- Home
- INTR vs HCM Comparison
INTR vs HCM Comparison
Compare INTR & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- HCM
- Stock Information
- Founded
- INTR 1994
- HCM 2000
- Country
- INTR Brazil
- HCM Hong Kong
- Employees
- INTR N/A
- HCM N/A
- Industry
- INTR
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- INTR
- HCM Health Care
- Exchange
- INTR Nasdaq
- HCM Nasdaq
- Market Cap
- INTR 2.1B
- HCM 2.3B
- IPO Year
- INTR N/A
- HCM N/A
- Fundamental
- Price
- INTR $5.21
- HCM $16.11
- Analyst Decision
- INTR Strong Buy
- HCM Hold
- Analyst Count
- INTR 3
- HCM 1
- Target Price
- INTR $7.30
- HCM $19.00
- AVG Volume (30 Days)
- INTR 2.2M
- HCM 71.4K
- Earning Date
- INTR 02-06-2025
- HCM 03-19-2025
- Dividend Yield
- INTR 1.55%
- HCM N/A
- EPS Growth
- INTR 176.00
- HCM N/A
- EPS
- INTR 0.33
- HCM N/A
- Revenue
- INTR $743,862,312.00
- HCM $610,806,000.00
- Revenue This Year
- INTR N/A
- HCM N/A
- Revenue Next Year
- INTR $17.41
- HCM $15.89
- P/E Ratio
- INTR $15.42
- HCM N/A
- Revenue Growth
- INTR 43.28
- HCM N/A
- 52 Week Low
- INTR $3.88
- HCM $12.84
- 52 Week High
- INTR $7.84
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- INTR 51.92
- HCM 68.69
- Support Level
- INTR $5.05
- HCM $13.58
- Resistance Level
- INTR $5.63
- HCM $13.96
- Average True Range (ATR)
- INTR 0.23
- HCM 0.31
- MACD
- INTR -0.02
- HCM 0.34
- Stochastic Oscillator
- INTR 27.59
- HCM 89.84
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.